<DOC>
	<DOCNO>NCT00664326</DOCNO>
	<brief_summary>This uncontrolled , open-label , non-randomized Phase II study oral BAY73-4506 evaluate response rate BAY73-4506 previously untreated patient metastatic unresectable renal cell cancer ( RCC ) .</brief_summary>
	<brief_title>A Phase II Uncontrolled Study BAY73-4506 Previously Untreated Patients With Metastatic Unresectable RCC</brief_title>
	<detailed_description>The final analysis efficacy perform last patient treat least 6 month . Additional periodic safety efficacy data review perform patient continue receive study drug afterwards .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Male female patient &gt; /= 18 year age . Patients , suffer unresectable and/or metastatic , measurable predominantly clear cell RCC ( renal cell carcinoma histologically ) cytologically document . Patients must previously untreated advanced disease . Prior palliative radiation therapy allow target lesion ( ) include within radiation field 30 % bone marrow irradiate . Patients least one unidimensional measurable lesion compute tomography ( CTscan ) magnetic resonance imaging ( MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) . Patients `` Intermediate '' `` Low '' risk per Motzer score . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate bone marrow , renal hepatic function assess follow laboratory requirement conduct within 7 day prior study drug treatment Patients receive prior systemic treatment regimens RCC . Uncontrolled/unstable cardiac disease Uncontrolled hypertension Active clinically serious infection ( &gt; Common Terminology Criteria Adverse Events [ CTCAE ] grade 2 ) History human immunodeficiency virus ( HIV ) infection chronic hepatitis B C. Known history symptomatic metastatic brain meningeal tumours Patients seizure disorder require medication Patients evidence history bleed diathesis . Any hemorrhage bleeding event &gt; /= CTCAE Grade 3 within 4 week first dose study . Pregnant breastfeeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
</DOC>